Rigel Pharmaceuticals, Inc./$RIGL

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX

About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Ticker

$RIGL
Primary listing

Industry

Biotechnology

Employees

163

ISIN

US7665597024

RIGL Metrics

BasicAdvanced
$338M
9.09
$2.08
1.29
-

Bulls say / Bears say

Rigel Pharmaceuticals reported a significant earnings surprise in Q3 2024, with earnings per share of $0.70, surpassing the consensus estimate of $0.01, indicating strong financial performance. (nasdaq.com)
Analysts have raised their price targets for Rigel Pharmaceuticals, with B. Riley increasing its target from $20.00 to $24.00, reflecting confidence in the company's growth prospects. (marketbeat.com)
Citigroup has upgraded Rigel Pharmaceuticals' stock price target from $40.00 to $49.00, indicating a positive outlook on the company's future performance. (americanbankingnews.com)
Insider selling activity, including CEO Raul R. Rodriguez selling 4,952 shares, may raise concerns about the company's future prospects. (etfdailynews.com)
StockNews.com downgraded Rigel Pharmaceuticals from a 'strong-buy' to a 'buy' rating, suggesting a less bullish stance on the stock. (defenseworld.net)
The recent settlement agreement allowing Annora Pharma to sell a generic version of TAVALISSE® in Q2 2032 could impact Rigel's long-term revenue from this product. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RIGL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs